SCHEMBL214790

SCHEMBL214790

NC(=O)c1[nH]cnc1C(=O)N(c1nc2ccccc2[nH]1)c1ccccc1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
POLB P06746 1/20 0.36
PAX8 Q06710 1/20 0.35
RAB9A P51151 5/20 0.35
NPC1 O15118 5/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CDK1 P06493 1/20 0.35
CDK2 P24941 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
PDE10A Q9Y233 2/20 0.34
CYP3A4 P08684 1/20 0.33
MAP2 P11137 1/20 0.33
CHEK2 O96017 1/20 0.33
GSK3B P49841 1/20 0.33
GBA1 P04062 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214647 0.86 POLB (0.38) HPGDHTTPOLBPAX8RAB9A
SCHEMBL214715 0.86 POLB (0.40) HPGDHTTPOLBPAX8RAB9A
SCHEMBL215645 0.85 POLB (0.37) HPGDHTTPOLBPAX8RAB9A
SCHEMBL215369 0.84 POLB (0.41) HPGDHTTPOLBPAX8RAB9A
SCHEMBL214873 0.84 LMNA (0.39) HPGDHTTPOLBPAX8RAB9A
SCHEMBL216886 0.83 POLB (0.36) HPGDHTTPOLBPAX8RAB9A
SCHEMBL214273 0.83 POLB (0.38) HPGDHTTPOLBPAX8RAB9A
SCHEMBL215596 0.83 POLB (0.38) HPGDHTTPOLBPAX8RAB9A
SCHEMBL214785 0.83 POLB (0.36) HPGDHTTPOLBPAX8RAB9A
SCHEMBL216075 0.83 POLB (0.38) HPGDHTTPOLBPAX8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 HPGD 3138/4885HTT 1059/4885POLB 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.